Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aptamer 1-MNV-siTriple
- Development stage
- Preclinical
- Lead developer
- Mayo Clinic
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Aptamer 1-MNV-siTriple is a preclinical targeted RNA therapeutic being developed by the Mayo Clinic for the treatment of cholangiocarcinoma (CCA). The therapeutic platform consists of milk-derived nanovesicles (MNVs) decorated with a novel, highly specific DNA aptamer ('Aptamer 1') that targets CCA cells. The MNVs are loaded with a combination of three small interfering RNAs (siRNAs), collectively referred to as 'siTriple', which target Yes-associated protein 1 (Yap), WW domain-containing transcription regulator protein 1 (Wwtr1/TAZ), and tyrosine-protein kinase Lck (Lck). By knocking down these three key genes involved in CCA pathobiology, Aptamer 1-MNV-siTriple reduces tumor cell proliferation and enhances apoptosis, offering a precise, targeted gene therapy approach with minimal off-target effects on adjacent healthy liver tissue.
- Other names
- Aptamer 1-siTripleAptamer1-siTripleAptamer-1-siTripleAptamer 1-MNV-siYap/Wwtr1/Lck
Beyond the preview
Go deeper on Aptamer 1-MNV-siTriple.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aptamer 1-MNV-siTriple.